Skip to main content
eScholarship
Open Access Publications from the University of California

From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations.

  • Author(s): Veit, Gudio
  • Avramescu, Radu G
  • Chiang, Annette N
  • Houck, Scott A
  • Cai, Zhiwei
  • Peters, Kathryn W
  • Hong, Jeong S
  • Pollard, Harvey B
  • Guggino, William B
  • Balch, William E
  • Skach, William R
  • Cutting, Garry R
  • Frizzell, Raymond A
  • Sheppard, David N
  • Cyr, Douglas M
  • Sorscher, Eric J
  • Brodsky, Jeffrey L
  • Lukacs, Gergely L
  • et al.
Abstract

More than 2000 mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) have been described that confer a range of molecular cell biological and functional phenotypes. Most of these mutations lead to compromised anion conductance at the apical plasma membrane of secretory epithelia and cause cystic fibrosis (CF) with variable disease severity. Based on the molecular phenotypic complexity of CFTR mutants and their susceptibility to pharmacotherapy, it has been recognized that mutations may impose combinatorial defects in CFTR channel biology. This notion led to the conclusion that the combination of pharmacotherapies addressing single defects (e.g., transcription, translation, folding, and/or gating) may show improved clinical benefit over available low-efficacy monotherapies. Indeed, recent phase 3 clinical trials combining ivacaftor (a gating potentiator) and lumacaftor (a folding corrector) have proven efficacious in CF patients harboring the most common mutation (deletion of residue F508, ΔF508, or Phe508del). This drug combination was recently approved by the U.S. Food and Drug Administration for patients homozygous for ΔF508. Emerging studies of the structural, cell biological, and functional defects caused by rare mutations provide a new framework that reveals a mixture of deficiencies in different CFTR alleles. Establishment of a set of combinatorial categories of the previously defined basic defects in CF alleles will aid the design of even more efficacious therapeutic interventions for CF patients.

Main Content
Current View